The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 15, Issue 10, Pages 1219-1229
Publisher
Informa UK Limited
Online
2015-09-25
DOI
10.1586/14737175.2015.1086269
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A brief summary of the articles appearing in this issue of Biological Psychiatry.
- (2015) BIOLOGICAL PSYCHIATRY
- Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: A role for serotonin 5-HT1A and 5-HT2A receptors
- (2015) Tamaki Ishima et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator
- (2015) Noriko Yoshimi et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
- (2015) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
- (2015) John M. Kane et al. SCHIZOPHRENIA RESEARCH
- The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
- (2014) J. Peuskens et al. CNS DRUGS
- Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms
- (2014) Matthias Oelke et al. Expert Opinion On Drug Safety
- New Treatment Targets to Improve Symptoms in Schizophrenia
- (2014) Leslie Citrome JOURNAL OF CLINICAL PSYCHIATRY
- Prazosin in the Treatment of PTSD
- (2014) BEN GREEN Journal of Psychiatric Practice
- Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy
- (2014) Zofia Rogóż Pharmacological Reports
- Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors
- (2014) Noriko Yoshimi et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- α2-Adrenoceptors are targets for antipsychotic drugs
- (2014) Jan Brosda et al. PSYCHOPHARMACOLOGY
- Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
- (2014) Nevena Divac et al. Biomed Research International
- Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy
- (2013) Leslie Citrome ADVANCES IN THERAPY
- Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy
- (2013) Leslie Citrome ADVANCES IN THERAPY
- A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach
- (2013) Leslie Citrome CNS DRUGS
- Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms
- (2013) Stephen M. Stahl CNS SPECTRUMS
- Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
- (2013) Leslie Citrome Expert Opinion on Drug Metabolism & Toxicology
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes
- (2013) Glen I. Spielmans et al. PLOS MEDICINE
- Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia
- (2012) H. Y. Meltzer et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells by Ifenprodil: The Role of Sigma-1 and IP3 Receptors
- (2012) Tamaki Ishima et al. PLoS One
- Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: Role played by PLC-γ, IP3 receptors
- (2011) Kanako Itoh et al. BRAIN RESEARCH
- Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
- (2011) Adrian Newman-Tancredi et al. PSYCHOPHARMACOLOGY
- The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
- (2011) Herbert Y. Meltzer et al. PSYCHOPHARMACOLOGY
- Aripiprazole in schizophrenia and schizoaffective disorder: A review
- (2010) Emmanuel Stip et al. CLINICAL THERAPEUTICS
- If at First You Donʼt Succeed
- (2010) K. Ryan Connolly et al. DRUGS
- Potentiation of nerve growth factor-induced neurite outgrowth by the ROCK inhibitor Y-27632: A possible role of IP3 receptors
- (2010) Takahiko Minase et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
- (2010) Joanna C. Neill et al. PHARMACOLOGY & THERAPEUTICS
- A Novel Target of Action of Minocycline in NGF-Induced Neurite Outgrowth in PC12 Cells: Translation Initiation Factor eIF4AI
- (2010) Kenji Hashimoto et al. PLoS One
- Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
- (2009) Lucy Y. Wang et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making
- (2009) Jan Volavka et al. EXPERT OPINION ON PHARMACOTHERAPY
- Structure-based discovery of low molecular weight compounds that stimulate neurite outgrowth and substitute for nerve growth factor
- (2009) Britney Williams et al. JOURNAL OF NEUROCHEMISTRY
- Antipsychotic drug actions on gene modulation and signaling mechanisms
- (2009) Raffaella Molteni et al. PHARMACOLOGY & THERAPEUTICS
- Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
- (2008) J. A. Lieberman et al. PHARMACOLOGICAL REVIEWS
- Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth by Fluvoxamine: Role of Sigma-1 Receptors, IP3 Receptors and Cellular Signaling Pathways
- (2008) Tomoko Nishimura et al. PLoS One
- Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: Role of sigma-1 receptors and IP3 receptors
- (2008) Tamaki Ishima et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
- (2008) Daniel E. Casey et al. PSYCHOPHARMACOLOGY
- Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
- (2007) Yuko Fujita et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now